Propofol in anesthesia. Mechanism of action, structure-activity relationships, and drug delivery.
Propofol (2,6-diisopropylphenol) is becoming the intravenous anesthetic of choice for ambulatory surgery in outpatients. It is extensively metabolized, with most of the administered dose appearing in the urine as glucuronide conjugates. Favorable operating conditions and rapid recovery are claimed as the main advantages in using propofol, whereas disadvantages include a relatively high incidence of apnea, and blood pressure reductions. Besides a literature summary of the pharmacodynamics, pharmacokinetics, toxicology, and clinical use, this review provides a deeper discussion on the current understanding of mechanism of action and structure-activity relationships, and recent findings on drug delivery technologies as applied to the improvement of propofol formulations. The action of propofol involves a positive modulation of the inhibitory function of the neurotransmitter gama-aminobutyric acid (GABA) through GABAA receptors. Recent results from recombinant human GABAA receptor experiments and findings from the work exploring the effects at other receptors (e.g., glycine, nicotinic, and M1 muscarinic receptors) are reviewed. Studies showing its antiepileptic and anxiolytic properties are also discussed. The structure-activity relationships (SAR) of series of alkylphenols and p-X-substituted congeners have been reinvestigated. Interestingly, unlike the other congeners tested sofar, p-iodo-2,6-diisopropylphenol displayed anticonvulsant and anticonflict effects, but not sedative-hypnotic and anesthetic properties. Due to its high lipid-solubility, propofol was initially formulated as a solution with the surfactant Cremophor EL, but the occurrence of pain on injection and anaphylactoid reactions prompted to search for alternative formulations. Results from using cyclodextrins, water-soluble prodrugs, and adopting Bodor's approach to the site-specific chemical delivery system (CDS), as well as the advantages provided by computer-controlled infusion systems, are examined in some detail.
Trapani
G
G
Dipartimento Farmaco-Chimico, Facoltà di Farmacia, Università degli Studi di Bari, Via Orabona 4, Bari, 70125, Italy. trapani@farmchim.uniba.it
Altomare
C
C
Liso
G
G
Sanna
E
E
Biggio
G
G
D018686:Anesthetics, Intravenous / Q000737:chemistry* / Q000493:pharmacokinetics / Q000494:pharmacology*; D003001:Cloning, Molecular; D016503:Drug Delivery Systems; D018756:GABA Antagonists / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology; D058787:GABA-A Receptor Antagonists; D006801:Humans; D015742:Propofol / Q000737:chemistry* / Q000493:pharmacokinetics / Q000494:pharmacology*; D011963:Receptors, GABA-A / Q000235:genetics; D013329:Structure-Activity Relationship
D018686:Anesthetics, Intravenous; D018756:GABA Antagonists; D058787:GABA-A Receptor Antagonists; D011963:Receptors, GABA-A; D015742:Propofol